Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
Cancer Medicine · 2023
DOI: 10.1002/cam4.5799 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ruben A Mesa und 20 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Primary Myelofibrosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Cancer Research UK, Gilead Sciences.
Abstract (Originalsprache)
Background
Myelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction ≥50% from baseline. However, this dichotomous assessment provides a limited view of clinically relevant symptomatic changes. Herein we evaluated longitudinal change from baseline in TSS over the continuous 24‐week period and individual symptom scores to obtain a more comprehensive understanding of symptom benefits experienced by patients with MF receiving therapy.
Methods
Longitudinal symptom change was evaluated using mixed‐effect model repeated measure (MMRM) methodology with individual item‐level analyses to complement the interpretation of the landmark symptom results in the completed phase III SIMPLIFY studies of momelotinib in MF. MMRM compared mean change in TSS from baseline with Week 24 using data from all patient visits. Generalized estimating equations were used to estimate item‐level odds ratios using multiple predictive imputations for missing data.
Results
Momelotinib and ruxolitinib groups reported similar overall symptom improvements, with a TSS difference of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
- Clinical Outcomes Solutions, Tucson, Arizona, USA.
- Guy's and St. Thomas' NHS Foundation Trust, London, UK.
- Mayo Clinic, Phoenix, Arizona, USA.
- University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Queens University, Belfast City Hospital Trust, Belfast, UK.
ORCID-Profile: Ruben A Mesa, Lysbeth Floden
Förderung
- Medical Research Council
- Cancer Research UK
- Gilead Sciences
Zitieren
APA
Mesa, R. A., Hudgens, S., Floden, L., Harrison, C. N., Palmer, J., Gupta, V., McLornan, D. P., McMullin, M. F., Kiladjian, J. J., Foltz, L., Platzbecker, U., Fox, M. L., Mead, A. J., Ross, D. M., Oh, S. T., Perkins, A., Leahy, M. F., Deheshi, S., Donahue, R., …, & Verstovsek, S. (2023). Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Medicine. https://doi.org/10.1002/cam4.5799
Vancouver
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, et al. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Medicine. 2023. doi:10.1002/cam4.5799
BibTeX
@article{Mesa2023,
author = {Mesa, Ruben A and Hudgens, Stacie and Floden, Lysbeth and Harrison, Claire N and Palmer, Jeanne and Gupta, Vikas and McLornan, Donal P and McMullin, Mary F and Kiladjian, Jean-Jaques and Foltz, Lynda and Platzbecker, Uwe and Fox, M Laura and Mead, Adam J and Ross, David M and Oh, Stephen T and Perkins, Andrew and Leahy, Michael F and Deheshi, Samineh and Donahue, Rafe and Klencke, Barbara J and Verstovsek, Srdan},
title = {Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5799}
}
EUVIMED